Novel Preclinical and Radiopharmaceutical Aspects of [68Ga]Ga-PSMA-HBED-CC: A New PET Tracer for Imaging of Prostate Cancer

• Päätekijät: Matthias Eder (Tekijä), Oliver Neels (Tekijä), Miriam Müller (Tekijä), Ulrike Bauder-Wüst (Tekijä), Yvonne Remde (Tekijä), Martin Schäfer (Tekijä), Ute Hennrich (Tekijä), Michael Eisenhut (Tekijä), Ali Afshar-Oromieh (Tekijä), Uwe Haberkorn (Tekijä), Klaus Kopka (Tekijä)
• Aineistotyyppi: Kirja
• Julkaistu: MDPI AG, 2014-06-01T00:00:00Z.
• Aiheet: article
• Linkit: Connect to this object online.

The detection of prostate cancer lesions by PET imaging of the prostate-specific membrane antigen (PSMA) has gained highest clinical impact during the last years. 68Ga-labelled Glu-urea-Lys(Ahx)-HBED-CC ([68Ga]Ga-PSMA-HBED-CC) represents a successful novel PSMA inhibitor radiotracer which has recent...